Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/10/2014)... One week ahead of its annual ... today it will extend compensation benefits to workers from ... workers displaced as a result of factory remediation, effective ... resulted in the closure of five factories for remediation. ... immediate safety concerns. In May, the Alliance—in a 50/50 ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... July 10, 2014 A Forever ... that gets clients off to a great start and ... believe in, has launched a new Eating Disorders section ... new section highlights:, , Different types ... Manual of Mental Disorders (DSM-IV), including anorexia nervosa, bulimia ...
(Date:7/10/2014)... new study from Colorado School of Public Health shows ... a major problem in the Navajo Nation and among ... Americans is abysmal with more than three times the ... Batliner, DDS, MBA, associate director of the Center for ... Health. "The number one problem is access to care." ...
(Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... Madonna Behen HealthDay Reporter , THURSDAY, April ... to expand research and improve understanding of cancer among ... by the President,s Cancer Panel. While minorities currently ... are expected to become the collective majority by the ...
... News) -- Your social status affects how your brain ... the new study, brain activity in volunteers was measured ... increased brain activity when shown information about others at ... had greater response to others like them, the investigators ...
... Center for Translational Social Neuroscience (CTSN) at Emory University ... to screen the effectiveness of drugs to treat autism. ... Emory researchers have shown enhances behavioral therapy for phobias ... female voles D-cycloserine, which is thought to facilitate learning ...
... common in Germany compared with the rest of Europe. Extensive ... in 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue ... Arztebl Int 2011; 108[15]; 249-54). A woman,s folic acid ... does not develop the neural tube defect commonly known as ...
... A new Henry Ford Hospital study takes a closer look ... side-effects of ACE inhibitor use facial, tongue and airway ... of treatment. Using a treatment protocol developed ... treated to reduce swelling, resulting in no tracheotomies to open ...
... of people in the US have periodontal disease, but that ... the links between oral disease and other systemic health issues ... no connection between medical and dental care for diabetic patients. ... host a symposium that brings dental and medical experts together ...
Cached Medicine News:Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 2Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 3Health News:Shared Social Status Boosts Brain Activity, Research Shows 2Health News:Social bonding in prairie voles helps guide search for autism treatments 2Health News:Social bonding in prairie voles helps guide search for autism treatments 3Health News:Study targets treatment for serious ACE inhibitor side effect 2Health News:New frontiers in diabetes: The oral health connection 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: